Brief: Cyclo Therapeutics Reports Positive Feedback From EMA On Trial Design For Niemann-Pick Disease Type C
18/05/2020 13:06
May 18 (Reuters) - Ctd Holdings Inc CTDH.PK :
* CYCLO THERAPEUTICS ANNOUNCES POSITIVE FEEDBACK FROM
EUROPEAN
MEDICINES AGENCY ON ITS PIVOTAL TRIAL DESIGN FOR TRAPPSOL CYCLO
FOR NIEMANN-PICK DISEASE TYPE C
Source text for Eikon: ID:nBwbYRxH7a
Further company coverage: CTDH.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cyclo Therapeutics
See all newsBrief: Rafael Holdings Completes Merger With Cyclo Therapeutics Following Shareholder Approvals
Cyclo Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Cyclo Therapeutics Inc Issues $2.5 Million Convertible Promissory Note To Rafael Holdings
U.S. STOCKS ON THE MOVE-McDonald, Uber, SolarWinds
Cyclo Therapeutics jumps on prelim late-stage data of genetic disorder drug